IN Brief:
- Nūmi has secured €3.7m in non-dilutive France 2030 funding through the i-Démo programme.
- Its process cultivates mammary cells before automated harvesting and multi-stage downstream purification.
- Funding will support scale-up, further human-milk bioactives, and preparations for industrial manufacturing.
Nūmi has secured €3.7 million in non-dilutive France 2030 funding to scale its mammary-cell culture platform for producing human-milk bioactives, supporting a shift from laboratory development towards larger and more industrially relevant bioprocessing.
The French company has been selected as an i-Démo laureate for its Numindus project. Nūmi says the funding will be used to increase bioprocess scale, develop another generation of human-milk bioactives, and prepare its technology for industrialisation.
Its production concept differs from conventional dairy processing and from fermentation platforms that use microorganisms to manufacture selected proteins. Nūmi cultures mammary cells under controlled conditions and provides nutrients and biological signals intended to stimulate the cells’ natural milk-production functions.
The company sources mammary cells through partnerships with hospitals and lactariums, then cultivates them in controlled environments. After the production stage, cells are separated from the liquid using automated processing equipment before downstream purification involving membranes, extraction methods, and chromatography.
That combination makes scale-up a full bioprocess problem rather than a matter of increasing culture volume alone. Upstream cell growth, biological productivity, harvesting, separation, and purification all have to remain sufficiently consistent as equipment size increases.
Nūmi has already reported reaching 50-litre bioreactor scale in-house. At that volume, parameters including oxygen transfer, agitation, shear stress, and process control become more prominent, providing a more useful indication of future manufacturing behaviour than small laboratory cultures.
The company’s larger ambition comes from the composition of human milk itself. Nūmi describes it as containing more than 1,500 bioactive molecules and highlights components including lactoferrin, human milk oligosaccharides, antibodies, fatty acids, taurine, DHA, and ARA.
Producing selected compounds through mammary-cell culture creates a different technical proposition from manufacturing a single purified protein in yeast or another microbial host. A mammary-cell platform may offer access to a broader range of naturally produced components, but keeping that biological output repeatable places considerable pressure on media formulation, cell-line stability, process monitoring, and downstream recovery.
The purification train will be particularly important as volumes increase. Membrane separation, extraction, and chromatography can all become significant contributors to cost, yield loss, water use, and processing time. Increasing bioreactor capacity is of limited commercial value if valuable compounds are then lost or become too expensive to recover at the required purity.
France 2030 support arrives at a stage when those engineering questions become harder to avoid. Early biotechnology work can demonstrate that cells produce a target material; industrialisation requires evidence that the process can be repeated for long enough, at sufficient scale, and within sufficiently narrow specifications to support a commercial food or nutrition ingredient.
Nūmi is also developing its manufacturing approach with eventual food-safety and regulatory requirements in mind. Its technical material refers to FDA and European Food Safety Authority expectations, although the current funding award is not a regulatory approval and no finished commercial product has been authorised through the announcement.
That distinction is important for a platform aimed initially at highly sensitive nutrition applications. Cell-derived food ingredients will need extensive compositional, safety, process, and quality documentation, particularly where the long-term ambition includes infant nutrition.
The company also sees applications beyond infant formula, including functional foods built around selected compounds associated with human milk. Broader markets could improve the economics of the platform if individual bioactives can be produced and purified at useful scale before a complete milk-replacement product becomes commercially realistic.
The latest award follows other financing secured by Nūmi, including European Innovation Council support. Such blended funding is common in industrial biotechnology because development expenditure rises rapidly once programmes move into larger bioreactors, downstream equipment, analytical systems, and regulatory preparation.
Capital alone will not settle the manufacturing case. Mammary cells are more complex to cultivate than many microbial production organisms, and maintaining productivity while controlling contamination, shear stress, nutrient supply, and batch consistency will determine whether larger volumes improve the process or merely make its weaknesses more expensive.
Nūmi’s 50-litre milestone gives the company a base from which to test those constraints at increasing scale. The €3.7 million award is intended to finance the next engineering steps rather than declare the technology industrially finished.
For now, the useful milestones will be less photogenic than the promise of recreated human milk: larger stable runs, repeatable composition, acceptable downstream yields, and a process that can be cleaned, controlled, and validated consistently. Industrial biotechnology tends to become much less magical once the fermenter gets bigger, which is precisely why those milestones matter.
